Jean Fanny, Tomasini Pascale, Barlesi Fabrice
Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Marseille, France.
Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Marseille, France Aix Marseille University, Inserm U911 CRO2, Marseille, France.
Ther Adv Med Oncol. 2017 Dec;9(12):769-779. doi: 10.1177/1758834017741074. Epub 2017 Dec 19.
Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 (programmed cell-death 1) treatments such as nivolumab and pembrolizumab in second line. More recently, atezolizumab (MDPL 3280A), a programmed cell-death-ligand 1 (PD-L1) inhibitor, was also studied in this setting. Here, we report a review of the literature assessing the efficacy, safety, and place of atezolizumab in the second-line treatment of advanced NSCLC. We performed a literature search of PubMed, American Society of Clinical Oncology, European Society of Medical Oncology and World Conference on Lung Cancer meetings. Atezolizumab showed a good tolerance profile and efficacy in comparison with docetaxel for second-line treatment of advanced NSCLC. Potential predictive biomarkers also have to be assessed.
晚期非小细胞肺癌（NSCLC）的预后仍然很差，最近免疫检查点抑制剂的发展以及二线治疗中抗程序性死亡蛋白1（PD-1）治疗药物如纳武单抗和派姆单抗的获批改变了这一状况。最近，程序性死亡配体1（PD-L1）抑制剂阿特珠单抗（MDPL 3280A）也在此背景下进行了研究。在此，我们报告一篇文献综述，评估阿特珠单抗在晚期NSCLC二线治疗中的疗效、安全性及地位。我们对PubMed、美国临床肿瘤学会、欧洲医学肿瘤学会和世界肺癌大会会议进行了文献检索。与多西他赛相比，阿特珠单抗在晚期NSCLC二线治疗中显示出良好的耐受性和疗效。还必须评估潜在的预测生物标志物。
